MCID: KLT001
MIFTS: 50

Klatskin's Tumor

Categories: Cancer diseases, Gastrointestinal diseases, Liver diseases, Rare diseases

Aliases & Classifications for Klatskin's Tumor

MalaCards integrated aliases for Klatskin's Tumor:

Name: Klatskin's Tumor 12 52 15 17
Klatskin Tumor 12 52 58 6 43 71
Hilar Cholangiocarcinoma 12 58 17
Perihilar Cholangiocarcinoma 52 71
Perihilar Extrahepatic Bile Duct Carcinoma 12
Hilar Cholangiocellular Carcinoma 12
Klatskin's Tumour 12
Klatskin Tumour 12
Hilar Cca 58

Characteristics:

Orphanet epidemiological data:

58
klatskin tumor
Inheritance: Not applicable; Age of onset: Adult; Age of death: adult;

Classifications:

Orphanet: 58  
Rare hepatic diseases


External Ids:

Disease Ontology 12 DOID:4927
MeSH 43 D018285
NCIt 49 C36077
SNOMED-CT 67 253017000 6492006
MESH via Orphanet 44 D018285
ICD10 via Orphanet 33 C24.0
UMLS via Orphanet 72 C0206702
Orphanet 58 ORPHA99978
UMLS 71 C0206702 C4045991

Summaries for Klatskin's Tumor

NIH Rare Diseases : 52 Klatskin tumors are are a type of cholangiocarcinoma that begins in an area called the hilum, where the left and right bile ducts join and leave the liver. It is the most common type of cholangiocarcinoma, accounting for more than half of all cases. Symptoms usually don't present until advanced stages of disease, when jaundice is the most common feature. Other symptoms include abdominal pain, unintentional weight loss, and a general feeling of being unwell (malaise ). The cause of Klatskin tumors is unknown. Studies suggest that a combination of genetic, environmental, and lifestyle factors (multifactorial ) likely influence whether a person will develop cholangiocarcinoma. Because Klatskin tumors are often discovered after they have spread, they can be challenging to treat. Surgical removal of the tumor and relief of bile duct blockage are the main goals of treatment.

MalaCards based summary : Klatskin's Tumor, also known as klatskin tumor, is related to sclerosing cholangitis and bilirubin metabolic disorder, and has symptoms including abdominal pain, icterus and malaise. An important gene associated with Klatskin's Tumor is MIR373 (MicroRNA 373), and among its related pathways/superpathways are Matrix Metalloproteinases and Colorectal Cancer Metastasis. The drugs Bilirubin and Bismuth have been mentioned in the context of this disorder. Affiliated tissues include liver, endothelial and colon, and related phenotypes are jaundice and extrahepatic cholestasis

Disease Ontology : 12 An intrahepatic cholangiocarcinoma arising near or at the confluence of the right and left hepatic ducts.

Wikipedia : 74 A Klatskin tumor (or hilar cholangiocarcinoma) is a cholangiocarcinoma (cancer of the biliary tree)... more...

Related Diseases for Klatskin's Tumor

Diseases related to Klatskin's Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 363)
# Related Disease Score Top Affiliating Genes
1 sclerosing cholangitis 31.0 GPT CEACAM5 ALB
2 bilirubin metabolic disorder 30.6 GPT ALB AFP
3 biliary papillomatosis 30.5 KRT7 CEACAM5
4 acute cholangitis 30.3 GPT CEACAM5 ALB
5 krukenberg carcinoma 30.3 KRT7 CEACAM5
6 appendix adenocarcinoma 30.2 KRT7 CEACAM5
7 cholangitis 30.2 GPT CEACAM5 ALB
8 adenocarcinoma 30.2 MMP9 MMP2 MALAT1 KRT7 CEACAM5 APC
9 tubular adenocarcinoma 30.1 KRT7 CEACAM5 AFP
10 choledocholithiasis 30.1 PCCA GPT CEACAM5 ALB
11 cystadenoma 30.1 KRT7 CEACAM5 AFP
12 bile duct cystadenocarcinoma 30.0 KRT7 CEACAM5 AFP
13 liver sarcoma 29.9 KRT7 CEACAM5 AFP
14 hepatic tuberculosis 29.9 GPT ALB AFP
15 biliary atresia 29.9 KRT7 GPT ALB
16 cholecystolithiasis 29.9 GPT CEACAM5
17 neuroendocrine carcinoma 29.8 KRT7 KRT19 CEACAM5
18 papillary adenocarcinoma 29.8 KRT7 KRT19 CEACAM5
19 liver cirrhosis 29.7 MALAT1 GPT ALB AFP
20 mucinous adenocarcinoma 29.7 KRT7 KRT19 CEACAM5
21 biliary tract benign neoplasm 29.7 KRT7 KRT19 CEACAM5 AFP
22 adenosquamous carcinoma 29.7 KRT7 KRT19 CEACAM5
23 pancreatic adenocarcinoma 29.5 MMP9 MMP2 MMP14 KRT19 APC ALB
24 intrahepatic cholangiocarcinoma 29.5 MMP9 KRT7 KRT19 APC ALB AFP
25 viral hepatitis 29.3 KRT19 GPT ALB AFP
26 cholangitis, primary sclerosing 29.2 PRRT2 PCCA KRT7 KRT19 GPT ALB
27 gastric adenocarcinoma 29.2 MMP9 MMP2 KRT7 CEACAM5 APC AFP
28 gallbladder cancer 29.1 MMP9 MMP2 MALAT1 KRT7 KRT19 CEACAM5
29 cholangiocarcinoma 29.0 MMP9 MIR373 MALAT1 KRT7 KRT19 CEACAM5
30 lung cancer susceptibility 3 28.5 MMP9 MMP2 MMP14 MALAT1 KRT7 KRT19
31 bile duct cancer 28.4 PCCA MMP2 KRT7 KRT19 GPT CEACAM5
32 bile duct adenocarcinoma 28.3 PRRT2 PCCA KRT7 KRT19 CEACAM5 ALB
33 pancreatic cancer 28.0 MMP9 MMP2 MMP14 MALAT1 KRT7 KRT19
34 bile duct disease 27.8 PRRT2 PCCA KRT7 KRT19 GPT CEACAM5
35 biliary tract disease 27.8 PRRT2 PCCA KRT7 KRT19 GPT CEACAM5
36 hepatocellular carcinoma 27.5 MMP9 MMP2 MMP14 MALAT1 KRT7 KRT19
37 extracranial arteriovenous malformation 10.6 MMP9 MMP2
38 focal myositis 10.6 MMP9 MMP2
39 lentigo maligna melanoma 10.6 MMP9 MMP2
40 acute transverse myelitis 10.6 MMP9 MMP2
41 transverse myelitis 10.6 MMP9 MMP2
42 spastic entropion 10.5 MMP9 MMP2
43 multicentric osteolysis-nodulosis-arthropathy spectrum 10.5 MMP2 MMP14
44 nasal cavity squamous cell carcinoma 10.5 MMP9 MMP2
45 winchester syndrome 10.5 MMP2 MMP14
46 cholestasis 10.4
47 rare tumor 10.4
48 odontogenic myxoma 10.4 MMP9 MMP2
49 light chain deposition disease 10.4 MMP9 MMP2 MMP14
50 colon adenoma 10.4 MMP2 MACC1 APC

Graphical network of the top 20 diseases related to Klatskin's Tumor:



Diseases related to Klatskin's Tumor

Symptoms & Phenotypes for Klatskin's Tumor

Human phenotypes related to Klatskin's Tumor:

58 31 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 jaundice 58 31 hallmark (90%) Very frequent (99-80%) HP:0000952
2 extrahepatic cholestasis 58 31 hallmark (90%) Very frequent (99-80%) HP:0012334
3 cholangiocarcinoma 58 31 hallmark (90%) Very frequent (99-80%) HP:0030153
4 hepatomegaly 58 31 frequent (33%) Frequent (79-30%) HP:0002240
5 lymphadenopathy 58 31 frequent (33%) Frequent (79-30%) HP:0002716
6 fatigue 58 31 occasional (7.5%) Occasional (29-5%) HP:0012378
7 fever 58 31 occasional (7.5%) Occasional (29-5%) HP:0001945
8 weight loss 58 31 occasional (7.5%) Occasional (29-5%) HP:0001824
9 abdominal pain 58 31 occasional (7.5%) Occasional (29-5%) HP:0002027
10 venous thrombosis 58 31 occasional (7.5%) Occasional (29-5%) HP:0004936

UMLS symptoms related to Klatskin's Tumor:


abdominal pain, icterus, malaise

GenomeRNAi Phenotypes related to Klatskin's Tumor according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-114 9.4 AFP
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 9.4 AFP
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-177 9.4 APC
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-29 9.4 AFP APC
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-49 9.4 APC
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-63 9.4 AFP
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-65 9.4 AFP
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.4 KRT7
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.4 APC
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-74 9.4 APC
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-75 9.4 AFP

MGI Mouse Phenotypes related to Klatskin's Tumor:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.17 AFP ALB APC KRT19 MBD2 MMP2

Drugs & Therapeutics for Klatskin's Tumor

Drugs for Klatskin's Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bilirubin Phase 4 69853-43-6, 635-65-4 21252250 5280352
2
Bismuth Phase 4 7440-69-9 16682734 105143
3
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
4
Trioxsalen Approved Phase 3 3902-71-4 5585
5 Dihematoporphyrin Ether Phase 3
6 Hematoporphyrins Phase 3
7 Dermatologic Agents Phase 3
8 Hematoporphyrin Derivative Phase 3
9 Ether Phase 3
10 Photosensitizing Agents Phase 3
11
Floxuridine Approved Phase 1, Phase 2 50-91-9 5790
12
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
13
Levoleucovorin Approved, Investigational Phase 2 68538-85-2
14
Trametinib Approved Phase 2 871700-17-3 11707110
15
Temoporfin Approved, Investigational Phase 2 122341-38-2
16
Hydroxychloroquine Approved Phase 2 118-42-3 3652
17
Bevacizumab Approved, Investigational Phase 2 216974-75-3
18
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
19
Lenvatinib Approved, Investigational Phase 2 417716-92-8
20
leucovorin Approved Phase 2 58-05-9 6006 143
21
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
22
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
23
Gemcitabine Approved Phase 2 95058-81-4 60750
24
Ceritinib Approved Phase 2 1032900-25-6
25
Fluorouracil Approved Phase 2 51-21-8 3385
26
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
27
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
28
Pancrelipase Approved, Investigational Phase 2 53608-75-6
29
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
30
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
31 Hematinics Phase 2
32
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
33 Hormones Phase 2
34 Calcium, Dietary Phase 2
35 Anti-Inflammatory Agents Phase 2
36 Antiprotozoal Agents Phase 2
37 Antiparasitic Agents Phase 2
38 Antirheumatic Agents Phase 2
39 Antimalarials Phase 2
40 Angiogenesis Inhibitors Phase 2
41 Antineoplastic Agents, Immunological Phase 2
42 Immunoglobulins Phase 2
43 Antibodies Phase 2
44 Mitogens Phase 2
45 Endothelial Growth Factors Phase 2
46 Antibodies, Monoclonal Phase 2
47 Trace Elements Phase 2
48 Micronutrients Phase 2
49 Vitamins Phase 2
50 Antidotes Phase 2

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 Effect of Preoperative Biliary Drainage on Postoperative Complications in Resectable Patients With Hilar Cholangiocarcinoma(Klatskin Tumor) Unknown status NCT00797121 Phase 4
2 Quality of Life in Patients With Unresectable Hilar Cholangiocarcinoma on Palliative Metallic Stent Versus Plastic Stent: A Randomized Control Trial Unknown status NCT00746538 Phase 4
3 Uncovered Self-expandable Metal Stent Versus DoubleLayer Plastic Stent for Malignant Hilar Stricture: a Prospective Randomized Multicenter Trial Unknown status NCT01125865 Phase 4
4 Efficacy and Cost Analysis of Plastic Stent Compare to Metallic Stent in Unresectable Complex Hilar Cholangiocarcinoma; a Randomized Controlled Trial Completed NCT00721175 Phase 4
5 Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study. Recruiting NCT04378023 Phase 4 Neoadjuvant Chemo-radiotherapy
6 Photodynamic Therapy With S-1 in the Patients With Unresectable Type III or IV Cholangiocarcinoma: A Prospective Randomized Trial With Open Label Control Completed NCT00869635 Phase 3 S-1 Chemotherapy
7 Sequential Preoperative Ipsilateral Hepatic Vein Embolization After Portal Vein Embolization to Induce Further Liver Regeneration in Patients With Hepatobiliary Malignancy Completed NCT00698880 Phase 2, Phase 3
8 Percutaneous Bilateral Versus Unilateral Metal Stent Placement for Hilar Cholangiocarcinoma : A Prospective Open-label Randomized Controlled Trial Recruiting NCT02108145 Phase 2, Phase 3
9 Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection Recruiting NCT03779035 Phase 3 Gemcitabine;Capecitabine
10 Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma Terminated NCT02082522 Phase 3 Photodynamic therapy-Photofrin;Chemotherapy regimen
11 Phase 1 Study of Liver Transplantation Combined With Neoadjuvant Radiochemotherapy for Unresectable Hilar Cholangiocarcinoma Unknown status NCT02178280 Phase 1, Phase 2
12 Photodynamic Therapy Using a Novel Photosensitizer in Locally Advanced Hilar Cholangiocarcinoma Unknown status NCT02725073 Phase 2
13 Downstaging of Unresectable Intrahepatic or Hilar Cholangiocellular Carcinoma by Selective Intra-arterial Floxuridine and Systemic Cisplatin and Gemcitabine. A Dose Finding Single Center Phase IIa Study Completed NCT01692704 Phase 1, Phase 2 Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin
14 Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma Completed NCT01093222 Phase 2 Erlotinib Hydrochloride;Sorafenib Tosylate
15 Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer Completed NCT02042443 Phase 2 Capecitabine;Fluorouracil;Leucovorin Calcium;Trametinib
16 Cholangiocarcinoma Detection Using an Intraoperative Fluorescence Image Guided Approach With Bevacizumab-IRDye 800CW Recruiting NCT03620292 Phase 1, Phase 2 Bevacizumab-IRDye800CW
17 Safety and Tumoricidal Effect of Low Dose Temoporfin Photodynamic Therapy in Patients With Inoperable Bile Duct Cancers (Foscan® Study) Recruiting NCT03003065 Phase 2 Temoporfin
18 A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Recruiting NCT04068194 Phase 1, Phase 2 Avelumab;Nedisertib
19 A Phase I/IIA Study of ABC294640 Alone and in Combination With Hydroxychloroquine Sulfate in the Treatment of Patients With Advanced, Unresectable Intra-hepatic, Perihilar and Extra-Hepatic Cholangiocarcinoma Recruiting NCT03377179 Phase 2 ABC294640;Hydroxychloroquine Sulfate 200 MG
20 REGORAFENIB AFTER FAILURE OF GEMCITABINE AND PLATINUM-BASED CHEMOTHERAPY FOR LOCALLY ADVANCED (NON RESECTABLE) AND METASTATIC INTRA-HEPATIC OR HILAR CHOLANGIOCARCINOMA: A Randomized Double-blinded Phase II Trial. Active, not recruiting NCT02162914 Phase 2 Regorafenib/active;Regorafenib/placebo
21 Hepatic Arterial Infusion Chemotherapy With Oxaliplatin, 5-fluorouracil and Bevacizumab Plus Intravenous Toripalimab for Advanced Biliary Tract Cancer Not yet recruiting NCT04217954 Phase 2
22 Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers: a Single-arm, Non-randomized, Single-center Clinical Trial and Biomarker Study Not yet recruiting NCT04211168 Phase 2 Toripalimab plus Lenvatinib
23 Phase II Trial of Modified FOLFIRINOX in Patients With Metastatic Biliary Tract Cancer After Failure of Gemcitabine/Cisplatin Chemotherapy Not yet recruiting NCT03778593 Phase 2 5-Fluorouracil;Leucovorin;Irinotecan;Oxaliplatin
24 Multi-center, Randomized, Controlled, Open-label Study of Deuteporfin Photodynamic Therapy Plus Stenting Versus Stenting Alone as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma Terminated NCT02955771 Phase 2
25 A Phase II Trial of LDK378 as the First or Second-line Therapy in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma Terminated NCT02374489 Phase 2 LDK378
26 Phase II Study of Stereotactic Body Radiotherapy (SBRT) and Chemotherapy for Unresectable Cholangiocarcinoma Followed by Liver Transplantation Terminated NCT01151761 Phase 2 Gemcitabine;Cisplatin;Carboplatin;Capecitabine;5FU
27 A Phase 2 Study of Low-Dose Fractionated Radiation Therapy to the Whole Liver in Combination With Gemcitabine and Cisplatin in Locally Advanced Mass-Forming Intrahepatic Cholangiocarcinoma Terminated NCT02254681 Phase 2 Gemcitabine;Cisplatin
28 Definitive Chemoradiation With Gemcitabine and Continuous 5- FU (Fluorouracil)Followed by High Dose Rate Brachytherapy or Stereotactic Body Radiation Therapy Boost in Locally Advanced Intra or Extrahepatic Cholangiocarcinoma Terminated NCT00983541 Phase 2 Fluorouracil (5-FU);Gemcitabine
29 A Phase I/II Dose Escalation Study to Assess the Safety, Tolerability and Efficacy of Amphinex®-Induced Photochemical Internalisation (PCI) of Gemcitabine in Patients With Advanced Inoperable Cholangiocarcinomas Completed NCT01900158 Phase 1 Amphinex, Gemcitabine and Cisplatin
30 A Phase I Study of ADH-1 and Gemcitabine Plus Cisplatin in Patients With Unresectable or Metastatic Pancreatic and Biliary Tract Cancers Completed NCT01825603 Phase 1 ADH-1;Cisplatin;Gemcitabine Hydrochloride
31 Phase I Dose Escalation Trial of External Beam Radiation and Cyberknife Radiosurgery Boost With Concurrent Capecitabine for Hilar Cholangiocarcinoma (Klatskin Tumor) Terminated NCT00630890 Phase 1
32 A Phase Ib, Open-Label, Dose- Escalation Trial of ACY-1215 in Combination With Gemcitabine and Cisplatin in Patients With Unresectable or Metastatic Cholangiocarcinoma Withdrawn NCT02856568 Phase 1 Cisplatin;Gemcitabine Hydrochloride;Ricolinostat
33 Impact of Three-dimensional Visualization on Operation Strategy and Complications for Hilar Cholangiocarcinoma Unknown status NCT03132649
34 Trapianto di Fegato Per Colangiocarcinoma (CCA) Ilare in Associazione a Radio e Chemioterapia Neoadiuvante Unknown status NCT01549795 Capecitabine
35 Superior Bilioenteric Anastomosis by Magnetic Compressive Technique: A Multicenter, Prospective, Randomized Controlled Trial Unknown status NCT02801500
36 Application of Endoscopic Scissors Cutting Endoscopic Nasobiliary Drainage Tube in the Treatment of Malignant Hilar Biliary Strictures: a Multicenter, Prospective, Randomized Controlled Study Unknown status NCT03353181
37 The Predictor of Infectious Complication After Hepatopancreatobiliary Surgery and Monitoring Indicator of Anti-infectious Therapy Unknown status NCT02878668
38 Optimization of Health Expenditure in Major Surgery: Impact of a Mixed, Clinical and Ethnographic Approach in the Model of Liver Surgery Unknown status NCT01715402
39 Randomized Clinical Trial Comparing Three Dimension Laparoscopic and Open Surgery for Perihiliar Cholangiocarcinoma Unknown status NCT03383796
40 Exploratory Phase IV Randomized Single Blind Study Evaluating the Efficacy and Tolerability of Hemopatch in Improving Time of Hemostasis and Preventing Post-operative Complications After Hepatic Resection Unknown status NCT03323359
41 Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection? Completed NCT00733200
42 Long-term Morbidity After Surgery for Perihilar Cholangiocarcinoma; a Cohort Study Completed NCT03999593
43 Single Versus Multiple Deployment of Metallic Stents for Inoperable Malignant Hilar Biliary Obstruction: A Multicenter Prospective Randomized Study Completed NCT02166970
44 The Role of Gadoxetate Enhanced Spectral Dual-Energy CT in Evaluating Hilar Cholangiocarcinoma Completed NCT01673802 Early Phase 1 CT scan
45 Split-in-situ Resection With Radio-frequency Ablation Instead of Liver Partition on the First Stage (RALPPS) in Patients With Hilar and Intrahepatic Cholangiocarcinoma Completed NCT03320980
46 Photodynamic Therapy With Polyhematoporphyrin for Malignant Biliary Obstruction - a Retrospective Analysis. Completed NCT02504957
47 Best Biliary Drainage Option in Type II、III、IV Klatskin Tumor:ERCP or PTBD Completed NCT03104582
48 Observational Study for Safety and Efficacy of Photodynamic Therapy for Bile Duct Invasion of Hepatocellular Carcinoma Completed NCT01506115 Photofrin
49 A Pilot Study to Determine the Feasibility of Stereotactic Body Radiation Therapy Following Chemotherapy for Unresectable Perihilar Cholangiocarcinoma. "The STRONG Trial" Recruiting NCT03307538
50 Effect of 37℃ Non-ionic Contrast Agent During ERCP Procedure in Hilar Cholangiocarcinoma: A Prospective Double-blind Multicenter Randomized Controlled Study Recruiting NCT03104569

Search NIH Clinical Center for Klatskin's Tumor

Cochrane evidence based reviews: klatskin tumor

Genetic Tests for Klatskin's Tumor

Anatomical Context for Klatskin's Tumor

MalaCards organs/tissues related to Klatskin's Tumor:

40
Liver, Endothelial, Colon, B Cells, Lymph Node, Prostate, Testes

Publications for Klatskin's Tumor

Articles related to Klatskin's Tumor:

(show top 50) (show all 286)
# Title Authors PMID Year
1
Methyl-CpG binding protein MBD2 is implicated in methylation-mediated suppression of miR-373 in hilar cholangiocarcinoma. 46
21165562 2011
2
A case of peribiliary hepatic cysts in a cirrhotic liver: A mimicker of Klatskin Tumor. 61
32435324 2020
3
Endoscopic Versus Percutaneous Preoperative Biliary Drainage in Patients With Klatskin Tumor Undergoing Curative Surgery: A Systematic Review and Meta-Analysis of Short-Term and Long-Term Outcomes. 61
32172684 2020
4
The Role of Portoenterostomy with Aggressive Hilar Dissection in Biliary Tract Tumors: Report of Case Series and Review of the Literature. 61
32410790 2020
5
There Is a Great Future in Plastics: Personalized Approach to the Management of Hilar Cholangiocarcinoma Using a 3-D-Printed Liver Model. 61
32440740 2020
6
Advanced laparoscopic HPB surgery: Experience in Seoul National University Bundang Hospital. 61
32490336 2020
7
Current status of laparoscopic radical hilar cholangiocarcinoma in Mainland China. 61
32389939 2020
8
Hepatobiliary and pancreatic surgery in the elderly: Current status. 61
32181422 2020
9
Nomograms predict survival outcome of Klatskin tumors patients. 61
32110489 2020
10
Klatskin-mimicking neuroendocrine tumor. 61
31696723 2019
11
Acute mental change as the presenting sign of posthepatectomy hepatic failure: A case report. 61
31770264 2019
12
Percutaneous Hepaticojejunostomy across an Isolated Bile Duct after Klatskin Tumor Resection. 61
31349977 2019
13
Clinical features of isolated proximal-type immunoglobulin G4-related sclerosing cholangitis. 61
30570170 2019
14
Radiotherapy or Chemoradiation in Unresectable Biliary Cancer: A Retrospective Study. 61
31177154 2019
15
Liver Transplant for Perihilar Cholangiocarcinoma (Klatskin Tumor): The Essential Role of Patient Selection. 61
29911960 2019
16
Klatskin Tumor: A Population-Based Study of Incidence and Survival. 61
31204730 2019
17
Heterotopic chondroid tissue of the main bile duct mimicking Klatskin tumor: case report and review of the literature. 61
30499056 2019
18
Primary large cell neuroendocrine carcinoma of the common hepatic duct mimicking a Klatskin tumor. 61
29466852 2019
19
Hepatic hilar mass in an adolescent: a rare case of hepatobiliary tuberculosis. 61
30832669 2019
20
Ultrasound-guided percutaneous irreversible electroporation of hepatic and abdominal tumors not eligible for surgery or thermal ablation: a western report on safety and efficacy. 61
30843171 2019
21
Klatskin tumors and "Klatskin-mimicking lesions": our 22-year experience. 61
30421957 2019
22
Concomitant adenosquamous carcinoma and cystadenocarcinoma of the extrahepatic bile duct: A case report. 61
30705898 2019
23
Preoperative Portal Vein Embolization Alone with Biliary Drainage Compared to a Combination of Simultaneous Portal Vein, Right Hepatic Vein Embolization and Biliary Drainage in Klatskin Tumor. 61
30238334 2018
24
[Cavernoma complicated with biliopatia secondary to type 1 Gaucher disease: report of a Peruvian case]. 61
30540732 2018
25
IgG4-related sclerosing cholangitis mimicking hilar cholangiocarcinoma (Klatskin tumor): a case report of a challenging disease and review of the literature. 61
31579779 2018
26
Patient With Unresectable Cholangiocarcinoma Treated With Radiofrequency Hyperthermia in Combination With Chemotherapy: A Case Report. 61
28745084 2018
27
Metastatic Pancreatic Adenocarcinoma Presenting as a Klatskin Tumor. 61
30568968 2018
28
Gerald Klatskin (1910-1986): A pioneer in hepato-biliary disorders and biopsy techniques. 61
29998747 2018
29
[Cholangiocellular cancer: the state of the problem and ways to improve the results of surgical treatment]. 61
30560842 2018
30
Mirizzi Syndrome: Diagnosis and Management of a Challenging Biliary Disease. 61
30159303 2018
31
Klatskin Tumor. 61
28985102 2017
32
Best option for preoperative biliary drainage in Klatskin tumor: A systematic review and meta-analysis. 61
29069029 2017
33
Hepatoduodenal lymph node metastasis mimicking Klatskin tumor in a patient with sigmoid colon mucinous cancer. 61
28828110 2017
34
Single synchronous liver metastasis from Merkel cell carcinoma mimicking a klatskin tumor: A diagnostic challenge. 61
28473299 2017
35
Preoperative biliary drainage versus direct surgery for perihilar cholangiocarcinoma: A retrospective study at a single center. 61
28529266 2017
36
Primary Hepatic Lymphoma Mimicking Cholangiocarcinoma. 61
28804587 2017
37
Primary extrahepatic bile duct neuroendocrine tumor with obstructive jaundice masquerading as a Klatskin tumor. 61
28596824 2017
38
Evaluation of Tumor Markers and Their Impact on Prognosis in Gallbladder, Bile Duct and Cholangiocellular Carcinomas - A Pilot Study. 61
28373474 2017
39
Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications. 61
28405328 2017
40
Mortality after portal vein embolization: Two case reports. 61
28178122 2017
41
Extrahepatic biliary obstrution secondary to neuroendocrine tumor of the common hepatic duct. 61
27902955 2017
42
Best options for preoperative biliary drainage in patients with Klatskin tumors. 61
27287904 2017
43
Bilateral ovarian metastasis of a Klatskin tumor: A rare case. 61
28913125 2016
44
A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer. 61
27586966 2016
45
Associating Liver Partition and Portal Vein Ligation for Primary Hepatobiliary Malignancies and Non-Colorectal Liver Metastases. 61
26929296 2016
46
Isolated Liver Hilar Infiltration by IgG4 Inflammation Mimicking Cholangiocarcinoma. 61
27843427 2016
47
The Klatskin Tumor That Wasn't: An Unusual Presentation of Sarcoidosis. 61
27761479 2016
48
Y-configured metallic stent combined with (125)I seed strands cavity brachytherapy for a patient with type IV Klatskin tumor. 61
27648091 2016
49
Palliative Locoregional Treatment for Unresectable Nonmetastatic Klatskin Tumor: Percutaneous Transhepatic Biliary Drainage Combined With 3-dimensional Conformal Radiotherapy. 61
27035079 2016
50
[Operation treatment method of Bismuth-Corlette Ⅲ, Ⅳ hilar cholangiocarcinoma]. 61
27373472 2016

Variations for Klatskin's Tumor

ClinVar genetic disease variations for Klatskin's Tumor:

6 ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 APC NM_000038.6(APC):c.4658C>T (p.Ala1553Val)SNV Uncertain significance 559953 rs1554086050 5:112175949-112175949 5:112840252-112840252

Expression for Klatskin's Tumor

Search GEO for disease gene expression data for Klatskin's Tumor.

Pathways for Klatskin's Tumor

Pathways related to Klatskin's Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.54 MMP9 MMP2 MMP14
2 11.47 MMP9 MMP2 MMP14 APC
3 11.4 MMP9 MMP2 APC
4 11.25 MMP9 MMP2 MMP14
5 11.12 MMP9 MMP2 MMP14
6 11.01 MMP9 MMP2 MMP14 CEACAM5

GO Terms for Klatskin's Tumor

Biological processes related to Klatskin's Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular matrix disassembly GO:0022617 9.33 MMP9 MMP2 MMP14
2 response to amyloid-beta GO:1904645 9.32 MMP9 MMP2
3 tissue remodeling GO:0048771 9.26 MMP2 MMP14
4 collagen catabolic process GO:0030574 9.13 MMP9 MMP2 MMP14
5 endodermal cell differentiation GO:0035987 8.8 MMP9 MMP2 MMP14

Molecular functions related to Klatskin's Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endopeptidase activity GO:0004175 8.8 MMP9 MMP2 MMP14

Sources for Klatskin's Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....